Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Nov 15:7:1797.
doi: 10.12688/f1000research.16786.1. eCollection 2018.

Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial

Asgeir Store Jakola  1   2   3 , Katja Werlenius  4   5 , Munila Mudaisi  6 , Sofia Hylin  7 , Sara Kinhult  8 , Jiri Bartek Jr  9   10 , Øyvind Salvesen  11 , Sven Magnus Carlsen  12   13 , Michael Strandéus  14 , Magnus Lindskog  15   16 , David Löfgren  17 , Bertil Rydenhag  1   3 , Louise Carstam  1   3 , Sasha Gulati  2   18 , Ole Solheim  2   18 , Jiri Bartek  19   20 , Tora Solheim  21   22
Affiliations

Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial

Asgeir Store Jakola et al. F1000Res. .

Abstract

Background: Disulfiram (DSF) is a well-tolerated, inexpensive, generic drug that has been in use to treat alcoholism since the 1950s. There is now independent preclinical data that supports DSF as an anticancer agent, and experimental data suggest that copper may increase its anti-neoplastic properties. There is also some clinical evidence that DSF is a promising anticancer agent in extracranial cancers. In glioblastoma, DSF induced O 6-methylguanine methyltransferase (MGMT) inhibition may increase response to alkylating chemotherapy. A recent phase I study demonstrated the safety of DSF in glioblastoma patients when DSF was administered at doses below 500 mg/day together with chemotherapy. We plan to assess the effects of DSF combined with nutritional copper supplement (DSF-Cu) as an adjuvant to alkylating chemotherapy in glioblastoma treatment. Methods: In an academic, industry independent, multicenter, open label randomized controlled phase II/III trial with parallel group design (1:1) we will assess the efficacy and safety of DSF-Cu in glioblastoma treatment. The study will include 142 patients at the time of first recurrence of glioblastoma where salvage therapy with alkylating chemotherapy is planned. Patients will be randomized to treatment with or without DSF-Cu. Primary end-point is survival at 6 months. Secondary end-points are overall survival, progression free survival, quality of life, contrast enhancing tumor volume and safety. Discussion: There is a need to improve the treatment of recurrent glioblastoma. Results from this randomized controlled trial with DSF-Cu in glioblastoma will serve as preliminary evidence of the future role of DSF-Cu in glioblastoma treatment and a basis for design and power estimations of future studies. In this publication we provide rationale for our choices and discuss methodological issues. Trial registration: The study underwent registration in EudraCT 2016-000167-16 (Date: 30.03.2016,) and Clinicaltrials.gov NCT02678975 (Date: 31.01.2016) before initiating the study.

Keywords: Randomized controlled trial; alkylating agents; brain tumor; disulfiram; glioblastoma; glioma.

PubMed Disclaimer

Conflict of interest statement

No competing interests were disclosed.

Figures

Figure 1.
Figure 1.. Flow-chart of patient screening, inclusion and follow-up.
See this image and copyright information in PMC

References

    1. Rønning PA, Helseth E, Meling TR, et al. : A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro Oncol. 2012;14(9):1178–1184. 10.1093/neuonc/nos153 - DOI - PMC - PubMed
    1. Stupp R, Mason WP, van den Bent MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. 10.1056/NEJMoa043330 - DOI - PubMed
    1. Hegi ME, Liu L, Herman JG, et al. : Correlation of O 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008;26(25):4189–4199. 10.1200/JCO.2007.11.5964 - DOI - PubMed
    1. Seystahl K, Wick W, Weller M: Therapeutic options in recurrent glioblastoma--An update. Crit Rev Oncol Hematol. 2016;99:389–408. 10.1016/j.critrevonc.2016.01.018 - DOI - PubMed
    1. Weller M, van den Bent M, Hopkins K, et al. : EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395–403. 10.1016/S1470-2045(14)70011-7 - DOI - PubMed

Publication types

MeSH terms

Associated data